MedTrace Logo

Effectiveness of a Walking Program Modulating Cardioreparative Factors in Heart Failure

NCT00937443 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 9

Last updated 2017-04-04

No results posted yet for this study

Summary

The incidence of heart failure grows as the population continues to age. Heart failure incidence approaches 10 per 1,000 persons after the age of 65. Although pharmacotherapy improves the treatment of heart failure it remains insufficient in preventing the progression of this debilitating disease. Cell based therapy has gained great strides over the last decade, launching cellular therapy into the mix of artillery for the treatment of chronic heart failure and coronary disease. While early pre-clinical work demonstrates that stem cell based therapy improves heart failure the exact mechanism in which these endothelial progenitor cells (EPC's) are recruited from the bone marrow, proliferate under the mediation of growth factors, and migrate to the injured tissues endogenously still remains obscured. Therefore in order for clinicians and scientist to impact heart failure treatment, a greater understanding of the physiological changes in EPC's and other modulators of cardioreparative process need further investigation.

Conditions

Interventions

OTHER

Physical Fitness

Does intensity of aerobic walking exercise modify cardiac reparative factors

BIOLOGICAL

Walking Exercise Group

Walking Group will increase intensity, duration, and steps of walking per week.

Sponsors & Collaborators

  • Vanderbilt University Medical Center

    lead OTHER

Principal Investigators

  • Douglas B Saywer, MD, PhD · Vanderbilt Heart and Vascular Institute

Eligibility

Min Age
30 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-07-31
Primary Completion
2014-01-31
Completion
2014-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00937443 on ClinicalTrials.gov